Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB022 With Paclitaxel and Carboplatin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BIIB022 in Combination with Paclitaxel and Carboplatin | EXPERIMENTAL | BIIB022 in Combination with Paclitaxel and Carboplatin |
| Name | Type | Description |
|---|---|---|
| BIIB022 With Paclitaxel and Carboplatin | DRUG | Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin |
Inclusion Criteria: * Age \>/= 18 years old * Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer * ECOG Performance Status 0 or 1 Exclusion Criteria: * History of another primary cancer within 3 years * Any prior or concurrent investigational or standard therapy for treatment of NSCLC * Pri...
Top 20 of 84 competitors
BIIB022 is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, and Solid Tumors. It is in Phase 1 clinical development and is not yet approved by the FDA.
BIIB022 is an anti-IGF-1R monoclonal antibody, meaning it targets the insulin-like growth factor 1 receptor (IGF-1R). By binding to this receptor, it is designed to interfere with signaling pathways that can promote tumor growth.
BIIB022 is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. The drug is currently in Phase 1 clinical trials for oncology indications.
BIIB022 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. All three clinical trials listed for BIIB022 are Phase 1 studies that have been completed.
BIIB022 has been studied in three completed Phase 1 trials: NCT00555724 in relapsed/refractory solid tumors, NCT00956436 in hepatocellular carcinoma combined with sorafenib, and NCT00970580 in non-small cell lung cancer combined with paclitaxel and carboplatin.
Yes, BIIB022 is an anti-IGF-1R monoclonal antibody. It is designed to target the insulin-like growth factor 1 receptor, which is implicated in tumor growth. This mechanism is being evaluated in Phase 1 trials for solid tumors, hepatocellular carcinoma, and non-small cell lung cancer.